Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split is part of a plan to regain compliance with Nasdaq listing requirements.
The Company's common stock is expected to begin trading on a split-adjusted basis on August 18, 2025.
Reverse Stock Split
Every 3 shares will be combined into 1, reducing outstanding shares to approximately 1.59 million.
Nasdaq Compliance
The reverse split aims to meet Nasdaq's minimum bid price requirement of $1.00 per share.
CEO Statement
Interim CEO highlighted the importance of maintaining Nasdaq listing for shareholder value enhancement.
- The reverse stock split will improve the Company's compliance with listing rules and potentially attract more investors.
- Reduced outstanding shares may lead to improved stock liquidity and a higher share price.
The reverse stock split marks a strategic move by Entero Therapeutics, Inc. to strengthen its Nasdaq listing position and enhance shareholder value in the long run.